P
Peter C Gøtzsche
Researcher at Cochrane Collaboration
Publications - 426
Citations - 191584
Peter C Gøtzsche is an academic researcher from Cochrane Collaboration. The author has contributed to research in topics: Clinical trial & Systematic review. The author has an hindex of 90, co-authored 413 publications receiving 147009 citations. Previous affiliations of Peter C Gøtzsche include University of Copenhagen & Copenhagen University Hospital.
Papers
More filters
Journal ArticleDOI
Lessons From and Cautions About Noninferiority and Equivalence Randomized Trials
TL;DR: This work was referred to JAMA by the author and their paper (along with the peer reviews) referred to one of the authors' family of ARCHIVES specialty journals for further consideration.
Journal ArticleDOI
Somatostatin analogues for acute bleeding oesophageal varices.
TL;DR: The findings do not suggest a need for further placebo-controlled trials of the type reviewed here, and it is doubtful whether this effect on mortality might have been overlooked.
Journal ArticleDOI
What should be done to tackle ghostwriting in the medical literature
Peter C Gøtzsche,Jerome P. Kassirer,Karen L. Woolley,Elizabeth Wager,Adam Jacobs,Art Gertel,Cindy W. Hamilton +6 more
TL;DR: This debate examines how best to tackle ghostwriting in the medical literature from the perspectives of a researcher, an editor, and the professional medical writer.
Journal ArticleDOI
Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia
TL;DR: There seems to be no survival benefit of antifungal agents given prophylactically or empirically to patients with cancer complicated by neutropenia and these agents should be restricted to Patients with proved infection and those in randomised trials.
Journal ArticleDOI
Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis
TL;DR: Prednisolone in low doses—that is, no more than 15 mg daily—is highly effective in patients with rheumatoid arthritis The risk of adverse effects is acceptable in short, moderate, or long term use Oral low dose prednisolones may be used intermittently in Patients with r heumatoidthritis, particularly if the disease cannot be controlled by other means.